D-0374-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0374-2021 was initiated by Teva Pharmaceuticals USA on Apr 26, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 192,277 cartons/1 single dose vial per carton.

Recall details

Product Type
Drugs
Report Date
May 26, 2021
Initiation Date
Apr 26, 2021
Termination Date
Jun 4, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
192,277 cartons/1 single dose vial per carton

Product description

Leucovorin Calcium for Injection, equivalent to leucovorin 350 mg/vial (20 mg/mL), Rx Only, FOR IM or IV Use, Sterile, Teva Parenteral Medicines, Inc., Irvine, CA NDC 0703-5145-01; ALSO LABELED UNDER: NOVAPLUS, Manufactured By: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454 NDC 0703-5145-91 (Novaplus, a registered trademark of Vizient, Inc.)

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Product was distributed nationwide.

Code information

NDC 0703-5145-01: Lot # 31325332B, exp. date 08/2021, Lot # 31325756B, exp. date 09/2021 AND NDC 0703-5145-91: Lot # 31325685B, exp. date 09/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0374-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0374-2021. Report a data issue: hello@regdatalab.com.